JP2018536707A - エフロルニチンとスリンダクの固定用量複合製剤 - Google Patents

エフロルニチンとスリンダクの固定用量複合製剤 Download PDF

Info

Publication number
JP2018536707A
JP2018536707A JP2018543001A JP2018543001A JP2018536707A JP 2018536707 A JP2018536707 A JP 2018536707A JP 2018543001 A JP2018543001 A JP 2018543001A JP 2018543001 A JP2018543001 A JP 2018543001A JP 2018536707 A JP2018536707 A JP 2018536707A
Authority
JP
Japan
Prior art keywords
composition
amount
sulindac
tablet
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018543001A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018536707A5 (enExample
Inventor
パトリック シャノン
パトリック シャノン
ゴンザレス ロベルト カルロス ブラボー
ゴンザレス ロベルト カルロス ブラボー
ジーン ドゥカソウ
ジーン ドゥカソウ
Original Assignee
キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド
キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド, キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド filed Critical キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド
Priority claimed from PCT/US2016/059689 external-priority patent/WO2017075576A1/en
Publication of JP2018536707A publication Critical patent/JP2018536707A/ja
Publication of JP2018536707A5 publication Critical patent/JP2018536707A5/ja
Priority to JP2021186911A priority Critical patent/JP7592001B2/ja
Priority to JP2024079276A priority patent/JP2024102339A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
JP2018543001A 2015-10-30 2016-10-31 エフロルニチンとスリンダクの固定用量複合製剤 Withdrawn JP2018536707A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021186911A JP7592001B2 (ja) 2015-10-30 2021-11-17 エフロルニチンとスリンダクの固定用量複合製剤
JP2024079276A JP2024102339A (ja) 2015-10-30 2024-05-15 エフロルニチンとスリンダクの固定用量複合製剤

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562248810P 2015-10-30 2015-10-30
US62/248,810 2015-10-30
US201662358698P 2016-07-06 2016-07-06
US62/358,698 2016-07-06
EP16306430 2016-10-28
EP16306429 2016-10-28
EP16306429.8 2016-10-28
EP16306430.6 2016-10-28
PCT/US2016/059689 WO2017075576A1 (en) 2015-10-30 2016-10-31 Eflornithine and sulindac, fixed dose combination formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021186911A Division JP7592001B2 (ja) 2015-10-30 2021-11-17 エフロルニチンとスリンダクの固定用量複合製剤

Publications (2)

Publication Number Publication Date
JP2018536707A true JP2018536707A (ja) 2018-12-13
JP2018536707A5 JP2018536707A5 (enExample) 2019-12-05

Family

ID=57256487

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018543001A Withdrawn JP2018536707A (ja) 2015-10-30 2016-10-31 エフロルニチンとスリンダクの固定用量複合製剤
JP2021186911A Active JP7592001B2 (ja) 2015-10-30 2021-11-17 エフロルニチンとスリンダクの固定用量複合製剤
JP2024079276A Pending JP2024102339A (ja) 2015-10-30 2024-05-15 エフロルニチンとスリンダクの固定用量複合製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021186911A Active JP7592001B2 (ja) 2015-10-30 2021-11-17 エフロルニチンとスリンダクの固定用量複合製剤
JP2024079276A Pending JP2024102339A (ja) 2015-10-30 2024-05-15 エフロルニチンとスリンダクの固定用量複合製剤

Country Status (14)

Country Link
US (4) US10973790B2 (enExample)
EP (1) EP3368029B1 (enExample)
JP (3) JP2018536707A (enExample)
KR (3) KR20180069068A (enExample)
CN (1) CN108366982A (enExample)
AU (1) AU2016343851B2 (enExample)
BR (1) BR112018008651A2 (enExample)
CA (1) CA3003149C (enExample)
CL (1) CL2018001157A1 (enExample)
CO (1) CO2018005491A2 (enExample)
HK (1) HK1258284A1 (enExample)
IL (1) IL259009A (enExample)
MA (1) MA43114A (enExample)
MX (1) MX390899B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019534265A (ja) * 2016-10-06 2019-11-28 オーバス セラピューティクス インコーポレイテッド エフロルニチン投与用製剤
JP2022028814A (ja) * 2015-10-30 2022-02-16 キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド エフロルニチンとスリンダクの固定用量複合製剤
JP2022532766A (ja) * 2019-05-17 2022-07-19 キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド 家族性腺腫性ポリポーシスを処置するための方法
US12605349B2 (en) 2024-09-05 2026-04-21 Orbus Therapeutics, Inc. Methods of treating grade 3 astrocytoma

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119909027B (zh) * 2025-01-21 2025-11-18 福安药业集团宁波天衡制药有限公司 一种稳定的舒林酸片及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508971A (ja) * 2001-10-24 2005-04-07 アストラゼネカ アクチボラグ 製剤
WO2009022670A1 (ja) * 2007-08-10 2009-02-19 Takeda Pharmaceutical Company Limited 速崩壊性錠剤
US20100120727A1 (en) * 2008-11-12 2010-05-13 Kyphia Pharmaceuticals, Inc. Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof
JP2014058547A (ja) * 2007-07-19 2014-04-03 Takeda Chem Ind Ltd アログリプチンおよび塩酸メトホルミンを含有する固形製剤
WO2015054133A1 (en) * 2013-10-07 2015-04-16 Bristol-Myers Squibb Company Hiv treatment formulation of atazanavir and cobicistat
WO2015102400A1 (en) * 2013-12-30 2015-07-09 Hanmi Pharm. Co., Ltd. Composite formulation for oral administration comprising ezetimibe and rosuvastatin

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309442A (en) * 1977-07-11 1982-01-05 Merrell Toraude Et Compagnie Method for controlling fertility in mammals
US4330559A (en) 1977-07-11 1982-05-18 Merrell-Toraude Et Cie Method of treating benign prostatic hypertrophy
US4413141A (en) 1977-07-11 1983-11-01 Merrell Toraude Et Compagnie 2-(Difluoromethyl)-2,5-diaminopentanoic acid
US4499072A (en) 1982-11-29 1985-02-12 Merrell Dow Pharmaceuticals Inc. Process for treating diseases with ODC inhibitors
US4859452A (en) 1986-01-17 1989-08-22 Board Of Regents, The University Of Texas System Methods for the reduction of difluoromethylornithine associated toxicity
US4925835A (en) 1986-05-01 1990-05-15 Sloan-Kettering Institute For Cancer Research Aziridinyl putrescine containing compositions and their uses in treating prostate cancer
US5002879A (en) 1986-05-06 1991-03-26 Merrell Dow Pharmaceuticals Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
FR2706255B1 (fr) 1993-06-17 1995-10-27 Univ Rennes Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques.
US5843929A (en) 1996-03-22 1998-12-01 Mayo Foundation For Medical Education And Research Chemoprevention of metachronous adenomatous colorectal polyps
EP0886519A1 (en) * 1996-11-01 1998-12-30 Ilex Oncology, Inc. Sustained release formulation containing dfmo
US6486214B1 (en) 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
EP1067919A1 (en) 1998-03-28 2001-01-17 THE ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA Dfmo and sulindac combination in cancer chemoprevention
US7700568B2 (en) 1998-06-30 2010-04-20 Sloan-Kettering Institute For Cancer Research Uses of DNA-PK
WO2000038715A2 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. Use of an integrin antagonist and radiation in the treatment of neoplasia
US20050037090A1 (en) 1998-12-23 2005-02-17 Mckearn John P. Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent
US6753422B2 (en) 1999-03-01 2004-06-22 O'brien Thomas G. Odc allelic analysis method for assessing carcinogenic susceptibility
CA2373931A1 (en) 1999-05-17 2000-11-23 Richard Love Dfmo and celecoxib in combination for cancer chemoprevention and therapy
WO2001068076A2 (en) 2000-03-07 2001-09-20 Ilex Oncology, Inc. D-enantiomer of dfmo and methods of use thereof for treating cancer
US6602910B2 (en) 2000-03-07 2003-08-05 Ilex Oncology, Inc. D-enantiomer of DFMO and methods of use therefor
AU2001285232A1 (en) 2000-08-24 2002-03-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Alpha-difluoromethylornithine (dfmo) use in the human prostate
AU2002343609B2 (en) 2001-11-16 2008-12-11 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
EP1575584A4 (en) * 2002-11-29 2006-02-01 Forest Laboratories METHOD FOR THE TREATMENT OF ACUTE CHARACTERIZATION BY UNIFORM FORMING WITH IBUPROFEN AND OXYCODON
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
WO2007012019A2 (en) * 2005-07-18 2007-01-25 Horizon Therapeutics, Inc. Medicaments containing famotidine and ibuprofen and administration of same
WO2007075673A1 (en) 2005-12-20 2007-07-05 University Of Hawaii Treatment regimen for n-myc, c-myc, and l-myc amplified and overexpressed tumors
DK2043637T3 (da) * 2006-07-18 2012-05-07 Horizon Pharma Usa Inc Fremgangsmåder og medikamenter til administrering af ibuprofen
CA2694389C (en) 2007-08-01 2016-01-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A Treatment of pediatric tumors
US8283331B2 (en) 2007-10-09 2012-10-09 Children's Medical Center Corporation Methods to regulate miRNA processing by targeting Lin-28
WO2009052518A2 (en) * 2007-10-19 2009-04-23 Aspen Benefits Group, Llc Methods and compositions directed to reduction of facial hair hirsutism in females
CA2753844A1 (en) 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies
MX2011005731A (es) 2008-12-08 2011-06-21 Procter & Gamble Composicion para el ciudado personal en la forma de un articulo que tiene un recubrimiento hidrofobo residente en la superficie.
DK2430452T3 (da) 2009-05-14 2014-10-06 Univ Arizona State Carcinom-diagnose og behandlinger, baseret på odc1-genotype
SG176096A1 (en) 2009-05-20 2011-12-29 Ranbaxy Lab Ltd Liquid dosage forms of isotretinoin
CN101898978A (zh) 2009-05-31 2010-12-01 徐锋 依氟鸟氨酸前药和偶合物及其使用方法
US20110256161A1 (en) 2010-04-19 2011-10-20 Aminex Therapeutics Inc. Methods for enhancing immune response
EP2563936B1 (en) 2010-04-29 2018-03-14 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
EP2568978B1 (en) 2010-05-14 2019-04-24 Arizona Board of Regents on Behalf of University of Arizona Cancer prevention and treatment based on dietary polyamine content
US8853423B2 (en) * 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
NZ603581A (en) 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
EP2912193B1 (en) 2012-10-29 2018-08-29 Arizona Board of Regents on Behalf of University of Arizona Predictive markers for polyamine inhibitor cancer therapies
GB2513299A (en) 2013-03-12 2014-10-29 Cellact Pharma Gmbh Biomedizinzentrum Compounds for targeting cancer stem cells
CA2952771A1 (en) 2014-06-18 2015-12-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Carcinoma diagnosis and treatment based on odc1 genotype
JP2018507910A (ja) 2015-02-12 2018-03-22 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ジ・ユニバーシティ・オブ・アリゾナ 神経芽細胞腫を治療する方法
WO2017075576A1 (en) 2015-10-30 2017-05-04 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
JP2018536707A (ja) 2015-10-30 2018-12-13 キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド エフロルニチンとスリンダクの固定用量複合製剤

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508971A (ja) * 2001-10-24 2005-04-07 アストラゼネカ アクチボラグ 製剤
JP2014058547A (ja) * 2007-07-19 2014-04-03 Takeda Chem Ind Ltd アログリプチンおよび塩酸メトホルミンを含有する固形製剤
WO2009022670A1 (ja) * 2007-08-10 2009-02-19 Takeda Pharmaceutical Company Limited 速崩壊性錠剤
US20100120727A1 (en) * 2008-11-12 2010-05-13 Kyphia Pharmaceuticals, Inc. Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof
WO2015054133A1 (en) * 2013-10-07 2015-04-16 Bristol-Myers Squibb Company Hiv treatment formulation of atazanavir and cobicistat
WO2015102400A1 (en) * 2013-12-30 2015-07-09 Hanmi Pharm. Co., Ltd. Composite formulation for oral administration comprising ezetimibe and rosuvastatin

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CLINICAL CANCER RESEARCH, vol. 6(10), JPN6020033138, 2000, pages 3850 - 3854, ISSN: 0004552654 *
MEYSKENS F L; MCLAREN C E; PELOT D; ET AL: "DIFLUOROMETHYLORNITHINE PLUS SULINDAC FOR THE PREVENTION OF SPORADIC COLORECTAL ADENOMAS: 以下備考", CANCER PREVENTION RESEARCH, vol. VOL:1, NR:1, JPN5018008188, 14 April 2008 (2008-04-14), pages 32 - 38, ISSN: 0004552651 *
クリノリル錠 添付文書, JPN6020033141, 2009, ISSN: 0004552655 *
日本内科学会雑誌, vol. 100(2), JPN6020033146, 2011, pages 426 - 431, ISSN: 0004552656 *
治療, vol. 92(1), JPN6020033132, 2010, pages 187 - 194, ISSN: 0004552652 *
癌と化学療法, vol. 42(6), JPN6020033135, June 2015 (2015-06-01), pages 699 - 703, ISSN: 0004552653 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022028814A (ja) * 2015-10-30 2022-02-16 キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド エフロルニチンとスリンダクの固定用量複合製剤
US11925613B2 (en) 2015-10-30 2024-03-12 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
JP7592001B2 (ja) 2015-10-30 2024-11-29 キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド エフロルニチンとスリンダクの固定用量複合製剤
US12350246B2 (en) 2015-10-30 2025-07-08 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
JP2019534265A (ja) * 2016-10-06 2019-11-28 オーバス セラピューティクス インコーポレイテッド エフロルニチン投与用製剤
US11439612B2 (en) 2016-10-06 2022-09-13 Orbus Therapeutics, Inc. Formulations for administration of eflornithine
JP2023040218A (ja) * 2016-10-06 2023-03-22 オーバス セラピューティクス インコーポレイテッド 医薬組成物
JP7262118B2 (ja) 2016-10-06 2023-04-21 オーバス セラピューティクス インコーポレイテッド 医薬組成物およびその使用
JP7539175B2 (ja) 2016-10-06 2024-08-23 オーバス セラピューティクス インコーポレイテッド 医薬組成物
JP2022532766A (ja) * 2019-05-17 2022-07-19 キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド 家族性腺腫性ポリポーシスを処置するための方法
US12605349B2 (en) 2024-09-05 2026-04-21 Orbus Therapeutics, Inc. Methods of treating grade 3 astrocytoma

Also Published As

Publication number Publication date
EP3368029C0 (en) 2026-05-27
EP3368029A1 (en) 2018-09-05
MA43114A (fr) 2018-09-05
US20230172887A1 (en) 2023-06-08
MX390899B (es) 2025-03-21
MX2018005350A (es) 2018-08-14
CA3003149A1 (en) 2017-05-04
US20240173284A1 (en) 2024-05-30
JP7592001B2 (ja) 2024-11-29
AU2016343851B2 (en) 2022-04-07
IL259009A (en) 2018-07-31
US11925613B2 (en) 2024-03-12
EP3368029B1 (en) 2026-05-27
KR20180069068A (ko) 2018-06-22
CN108366982A (zh) 2018-08-03
CL2018001157A1 (es) 2018-09-07
US20200009098A1 (en) 2020-01-09
CO2018005491A2 (es) 2018-06-12
US10973790B2 (en) 2021-04-13
BR112018008651A2 (en) 2018-10-30
KR20260033630A (ko) 2026-03-10
JP2024102339A (ja) 2024-07-30
KR20240162560A (ko) 2024-11-15
HK1258284A1 (zh) 2019-11-08
US12350246B2 (en) 2025-07-08
JP2022028814A (ja) 2022-02-16
CA3003149C (en) 2023-10-31
AU2016343851A1 (en) 2018-05-10
US11529326B2 (en) 2022-12-20
US20210267926A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
US12350246B2 (en) Eflornithine and sulindac, fixed dose combination formulation
JP6480420B2 (ja) コルヒチンの徐放性製剤およびその使用方法
WO2017075576A1 (en) Eflornithine and sulindac, fixed dose combination formulation
US8318202B2 (en) Stable compositions of famotidine and ibuprofen
BR112012028035B1 (pt) formulação de liberação imediata
JP7431886B2 (ja) 新規テビペネムピボキシルの即放性および調節放出性経口剤形
JP2009527477A (ja) 低紅潮ナイアシン製剤
CA2615496A1 (en) Medicaments containing famotidine and ibuprofen and administration of same
CN114096240A (zh) 用于治疗家族性腺瘤性息肉病的方法
TWI743059B (zh) 二氟甲基鳥氨酸及舒林酸（ｓｕｌｉｎｄａｃ），固定劑量組合調配物
JP6697539B2 (ja) コルヒチンの徐放性製剤およびその使用方法
US20260137642A1 (en) Methods of treating patients having type 1 diabetes with eflornithine
US20150224056A1 (en) Pharmaceutical compositions of ibuprofen and famotidine
US20130236538A1 (en) Pharmaceutical compositions of ibuprofen and famotidine
HK40068311A (en) Methods for treating familial adenomatous polyposis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191024

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201201

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210719

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211117

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221128

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230306

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20230309

C141 Inquiry by the administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C141

Effective date: 20230309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230609

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230726

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20240209